Global Blood Therapeutics, Inc. (GBT)
| Market Cap | 1.64B |
| Revenue (ttm) | 210.87M |
| Net Income (ttm) | -309.58M |
| Shares Out | 65.10M |
| EPS (ttm) | -4.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,149,160 |
| Open | 25.59 |
| Previous Close | 25.68 |
| Day's Range | 24.50 - 25.97 |
| 52-Week Range | 22.67 - 41.73 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 61.84 (+145.1%) |
| Earnings Date | May 4, 2022 |
About GBT
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, wh...
Financial Performance
In 2021, GBT's revenue was $194.75 million, an increase of 57.31% compared to the previous year's $123.80 million. Losses were -$303.09 million, 22.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for GBT stock is "Buy." The 12-month stock price forecast is 61.84, which is an increase of 145.11% from the latest price.
News
Why Global Blood Therapeutics Stock Was Sickly Today
The bears pounced on the company despite a first-quarter bottom-line beat.
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
GBT Reports First Quarter 2022 Financial Results
Achieved Oxbryta ® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year
GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity, Equity and Inclusion and Corporate Governance Report Highlights Efforts to Deliver Lo...
Analysts Estimate Global Blood Therapeutics (GBT) to Report a Decline in Earnings: What to Look Out for
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2022, the compensation committee of GBT's board of di...
Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim ...
The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community...
Grant proposals accepted through April 22, 2022 Grant proposals accepted through April 22, 2022
GBT Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following inv...
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.
Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates
Global Blood (GBT) delivered earnings and revenue surprises of -19.30% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
GBT Reports Fourth Quarter and Full Year 2021 Financial Results
Achieved Oxbryta ® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More
Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial results...
Global Blood Therapeutics' Oxbryta Scores European Approval For Sickle Cell Disease
The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12 year...
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell ...
The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis – the cause of long-term complications of sickle cell dise...
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
Benzinga's weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. This week, in tribute to Black History Month, the duel...
Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT's Voxelotor for the Treatment of H...
LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) today announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has awarded a positive scientific opini...
GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conferen...
Global Blood (GBT) Gets FDA Nod for Oxbryta Label Expansion
The FDA approves Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to less the 12 years, and NDA for a pediatric weight-based formulation of the drug.
U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Y...
New dispersible tablet dosage form also approved
GBT's Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sick...
European Commission decision on marketing authorization anticipated first quarter of 2022